A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer

Study acronym: IMPROVE
StatusActive, Not Recruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Sep 20, 2026 → Sep 20, 2027
See other at-risk trials from Memorial Sloan Kettering Cancer Center

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Sep 20, 2026 to Sep 20, 2027
    • Eligibility criteria expanded, about 15 words
    • Secondary endpoints: details revised at 10 of 10 entries
    • Publications: details revised at 2 of 2 entries
  2. Enrollment closed, study ongoing
    • Site details revised at 7 of 7 sites
    v18
  3. Enrollment target: 480 to 324v17
  4. Primary and study completion dates: Sep 20, 2025 to Sep 20, 2026v16
  5. Site contacts updated at 7 of 7 sitesv15
Show 13 earlier versionsHide 13 earlier versions
  1. Eligibility criteria expanded, about 140 wordsv14
  2. Re-verified, no change to tracked fieldsv13
  3. Enrollment target: 240 to 480v12
  4. Primary and study completion dates: Sep 20, 2024 to Sep 20, 2025v11
  5. Re-verified, no change to tracked fieldsv10
  6. Secondary endpoints expanded, about 85 wordsv9
  7. Enrollment target: 200 to 240
    • Eligibility criteria expanded, about 39 words
    v8
  8. Primary and study completion dates: Sep 20, 2023 to Sep 20, 2024v7
  9. Eligibility criteria expanded, about 7 wordsv6
  10. Re-verified, no change to tracked fieldsv5
  11. Primary and study completion dates: Sep 20, 2022 to Sep 20, 2023
    • Eligibility criteria expanded, about 7 words
    v4
  12. Eligibility criteria shortened, about 16 wordsv3
  13. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The overarching long-term goal of the Integrative Medicine for Patient-reported Outcomes Values and Experience (IMPROVE) research program is to evaluate whether integrating a virtual mind-body programming, Integrative Medicine at Home (IM@Home), will improve patient perceived values, outcomes, and experiences as they undergo systemic cancer treatment such as chemotherapy, immunotherapy, radiotherapy, targeted agents, cytoreductive surgery.
Trial Details
NCT Number NCT05053230
Lead Sponsor Memorial Sloan Kettering Cancer Center
Conditions
(from sponsor)		 Head and Neck Cancer, Head and Neck Tumor, Thoracic Tumor, Thoracic Cancer, Gynecologic Cancer, Gynecologic Tumor, Melanoma, Ovarian Cancer
Related terms Genital Neoplasms, Female, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Thoracic Neoplasms
Enrollment 324 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov